The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel.
Bourdoumis, A Chrisofos, M Stasinou, T Christopoulos, Panagiotis Mourmouris, P Kostakopoulos, A Deliveliotis, C
Bourdoumis, A
Chrisofos, M
Stasinou, T
Christopoulos, Panagiotis
Mourmouris, P
Kostakopoulos, A
Deliveliotis, C
Citations
Altmetric:
Abstract
To investigate potential fluctuations in prostate cancer antigen 3 (PCA 3) scores in castration-resistant prostate cancer (CRPC) patients treated with docetaxel and investigate the assay as a potential prognostic factor.
Description
Date
2015-05
Publisher
Collections
Keywords
Type
Article
Citation
The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel. 2015, 35 (5):3075-9 Anticancer Res